tag:www.gov.uk,2005:/search/news-and-communicationsNews and communications2025-06-09T14:04:20+01:00HM 바카라 사이트tag:www.gov.uk,2005:/government/news/chikungunya-vaccine-ixchiq-temporarily-paused-in-people-aged-65-and-over-as-precautionary-measure2025-06-09T14:04:20+01:00Chikungunya vaccine (IXCHIQ) temporarily paused in people aged 65 and over as precautionary measureThis is a precautionary measure while the MHRA conducts the safety review.
tag:www.gov.uk,2005:/government/news/women-on-skinny-jabs-must-use-effective-contraception-mhra-urges-in-latest-guidance2025-06-05T00:01:03+01:00Women on 바카라 사이트skinny jabs바카라 사이트 must use effective contraception, MHRA urges in latest guidance Anyone who suspects that they바카라 사이트ve had an adverse reaction to their weight loss or diabetes medicine or suspects it is not a genuine product, should report it to the MHRA. tag:www.gov.uk,2005:/government/news/mhra-approves-aumolertinib-to-treat-non-small-cell-lung-cancer2025-06-03T00:00:00+01:00MHRA approves aumolertinib to treat non-small cell lung cancerAs with all products, we will keep its safety under close reviewtag:www.gov.uk,2005:/government/news/mhra-approves-polihexanide-to-treat-acanthamoeba-keratitis2025-05-23T00:00:00+01:00MHRA approves polihexanide to treat acanthamoeba keratitisAs with any medicine, the MHRA will keep the safety and effectiveness of polihexanide under close review.바카라 사이트 tag:www.gov.uk,2005:/government/news/mhra-approves-vaccine-to-protect-against-pneumococcal-infections-such-as-pneumonia-and-meningitis2025-05-15T17:11:51+01:00MHRA approves vaccine to protect against pneumococcal infections such as pneumonia and meningitisAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/mhra-approves-first-uk-treatment-for-congenital-thrombotic-thrombocytopenic-purpura-cttp2025-05-12T17:41:15+01:00MHRA approves first UK treatment for congenital thrombotic thrombocytopenic purpura (cTTP) As with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/mhra-approves-teprotumumab-as-the-first-uk-treatment-for-adults-with-moderate-to-severe-thyroid-eye-disease-ted2025-05-07T00:00:00+01:00MHRA approves teprotumumab as the first UK treatment for adults with moderate to severe Thyroid Eye Disease (TED)As with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/vimkunya-vaccine-approved-to-prevent-disease-caused-by-the-chikungunya-virus-in-people-12-years-of-age-and-older2025-05-01T16:51:31+01:00Vimkunya vaccine approved to prevent disease caused by the chikungunya virus in people 12 years of age and older The Medicines and Healthcare products Regulatory Agency (MHRA) has today (1 May 2025) approved a vaccine (Vimkunya) used to prevent disease caused by the chikungunya virus in people 12 years of age and older. tag:www.gov.uk,2005:/government/news/mhra-authorises-cancer-treatment-variation-with-an-administration-time-of-3-5-minutes2025-04-30T15:17:40+01:00MHRA authorises cancer treatment variation with an administration time of 3바카라 사이트5 minutesAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/acoramidis-approved-to-treat-wild-type-or-variant-transthyretin-amyloidosis-in-adults-with-cardiomyopathy2025-04-25T11:54:57+01:00Acoramidis approved to treat wild-type or variant transthyretin amyloidosis in adults with cardiomyopathyAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/obecabtagene-autoleucel-conditionally-approved-to-treat-adults-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukaemia2025-04-25T00:00:00+01:00Obecabtagene autoleucel conditionally approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/mhra-approves-first-uk-treatment-for-friedreichs-ataxia-omaveloxolone2025-04-23T16:26:45+01:00MHRA approves first UK treatment for Friedreich바카라 사이트s ataxia, omaveloxoloneAs with all products, we will keep its safety under close review.tag:www.gov.uk,2005:/government/news/marstacimab-approved-to-treat-patients-aged-12-years-and-above-weighing-at-least-35-kg-with-haemophilia-a-or-b2025-04-22T11:09:20+01:00Marstacimab approved to treat patients aged 12 years and above (weighing at least 35 kg) with haemophilia A or BAs with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/professor-claire-stewart-appointed-to-the-commission-on-human-medicines-as-three-members-reappointed2025-04-17T14:12:39+01:00Professor Claire Stewart appointed to the Commission on Human Medicines as three members reappointedThe appointment will involve a time commitment of 22 days per year. Remuneration for the role will be at a rate of £325 per attendance and preparation for meetings.
tag:www.gov.uk,2005:/government/news/trastuzumab-deruxtecan-approved-to-treat-adults-with-her2-positive-cancer-that-has-spread-or-cannot-be-removed-by-surgery2025-04-09T00:00:00+01:00Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that has spread or cannot be removed by surgery As with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/eplontersen-approved-to-treat-adults-with-rare-inherited-nerve-disease-or-polyneuropathy2025-04-04T11:34:24+01:00Eplontersen approved to treat adults with rare inherited nerve disease or polyneuropathyThe Medicines and Healthcare products Regulatory Agency (MHRA) has approved eplontersen (Wainzua) to treat adults with polyneuropathy associated with hereditary transthyretin amyloidosis (ATTRv), which is a rare progressive 바카라 사이트tag:www.gov.uk,2005:/government/news/world-first-as-mhra-approves-trofolastat-for-diagnostic-imaging-of-prostate-cancer-in-men2025-03-28T10:04:12+00:00World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men As with all products, the MHRA will keep its safety under close review.tag:www.gov.uk,2005:/government/news/new-study-shows-mhra-collaboration-with-hospital-dna-sequencing-service-cuts-time-to-diagnose-infections2025-03-07T17:07:02+00:00New study shows MHRA collaboration with hospital DNA sequencing service cuts time to diagnose infectionsIn a UK-first, the Medicines and Healthcare products Regulatory Agency (MHRA) and Barts Health NHS Trust have developed a DNA sequencing approach that can be implemented onsite in hospitals so they can diagnose bacterial inf바카라 사이트tag:www.gov.uk,2005:/government/news/triple-combination-medicine-deutivacaftortezacaftorvanzacaftor-approved-for-cystic-fibrosis2025-03-07T00:00:00+00:00Triple combination medicine deutivacaftor/tezacaftor/vanzacaftor approved for cystic fibrosisAs with all products, the MHRA will keep its safety under close reviewtag:www.gov.uk,2005:/government/news/lazertinib-approved-for-use-in-combination-with-amivantamab-for-the-treatment-of-adults-with-non-small-cell-lung-cancer2025-03-06T00:00:00+00:00Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer As with all products, the MHRA will keep its safety under close review.